Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency (CBZ)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by University of Pittsburgh
Sponsor:
Collaborators:
Novartis
Information provided by (Responsible Party):
David Perlmutter, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01379469
First received: June 15, 2011
Last updated: February 25, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2015
  Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Publications:
Burroughs A.K., and Thalheimer U., Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology. 51: 1894-6.
Dodson W., Carbamazepine and oxycarbazepine, Pediatric Epilepsy: Diagnosis and Therapy, P.J. Dodson W.E., Editor. 1993; Demos Publications: New York. 303-314.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):